Form 4: Stoke Therapeutics CMO Boosts Share Holdings

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, increased his direct beneficial ownership of common stock by 10,000 shares and received a grant of 20,000 performance stock units.

Summary

• Chief Medical Officer Barry Ticho acquired 10,000 shares of Stoke Therapeutics common stock on August 14, 2025.
• The acquisition was a result of the exercise or vesting of derivative securities, with a transaction price of $0.
• Following this transaction, Ticho directly beneficially owns 26,775 shares of common stock.
• Ticho was granted 20,000 Performance Stock Units (PSUs) on August 14, 2025, which represent a right to receive one share of common stock per unit upon achievement of certain performance criteria.
• Half of the newly granted PSUs will vest on August 14, 2025, and the remaining half will vest on August 14, 2026, subject to continued service to the Issuer.
• An additional 10,000 PSUs were disposed of via an 'M' transaction code on August 14, 2025, indicating their conversion into the common stock acquired.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-planned transaction.

Sentiment

Score: 7

Explanation: The filing indicates an increase in insider ownership and equity compensation, which generally signals management confidence and aligns interests with shareholders. The transactions are part of a pre-planned Rule 10b5-1 plan, which is a neutral factor.

Positives

• Increased insider ownership of common stock, signaling confidence in the company's future prospects.
• Grant of performance stock units aligns management incentives with shareholder value creation, contingent on performance criteria and continued service.

Future Outlook

NA

Industry Context

NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive signal due to increased insider ownership and alignment of management incentives.
• Employees: Reflects standard equity compensation practices for executives.

Next Steps

• Continued vesting of Performance Stock Units on August 14, 2026.

Key Dates

Recommendation

The filing indicates an increase in insider ownership through equity compensation, which is generally a positive signal of management confidence. However, this is a routine compensation event rather than an open market purchase, and the price of acquisition was $0, indicating vesting or exercise. While it aligns management's interests with shareholders, it does not provide new fundamental information to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and consider this information in conjunction with the company's broader financial performance and strategic outlook.

Keywords

Stoke Therapeutics, STOK, Insider Trading, Form 4, Barry Ticho, Chief Medical Officer, Stock Units, Equity Compensation, Biotechnology, Pharmaceuticals